Insuring Your Health
Advocates Of Flat-Fee Primary Care See Opening In GOP鈥檚 Market-Driven Approach
In direct primary care, a monthly fee covers routine care, limiting insurers' role. But does it really provide better value?
Health Industry
2,641 - 2,660 of 3,991 Results
-
-
Repeal & Replace Watch
Liberal Vermont Tests The Waters On GOP Health Care Overhaul
Vermont embarks on a six-year experiment to redesign health care and how it鈥檚 paid for.
-
Repeal & Replace Watch
A Safety-Net Medical Center Wrestles With Specter Of 鈥楻epeal鈥
San Mateo Medical Center is among hundreds of safety-net hospitals in California and across the country that stand to lose big if the federal government slashes support for Medicaid and insurance exchanges.
By Anna Gorman -
Repeal & Replace Watch
Congressman鈥檚 Ties To Foreign Biotech Draw Criticism
Rep. Chris Collins鈥 enthusiastic investments in Australian biotech company Innate Immunotherapeutics preceded share purchases by the Buffalo Republican鈥檚 family members, associates and political donors 鈥 raising questions from Washington, D.C., to Sydney.
By Rachel Bluth and Emily Kopp -
The Orphan Drug Machine
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
By Sarah Jane Tribble and Sydney Lupkin -
Travel Ban Spotlights U.S. Dependence On Foreign-Born Doctors
One in four doctors practicing in the U.S. is an international medical doctor. Many foreign-born doctors practice in parts of the country where there are doctor shortages.
-
Judge Upends Effort To Limit Charity Funding For Kidney Patients’ Insurance
A federal judge in Texas last month issued a preliminary injunction barring the government from enforcing a rule allowing insurers to refuse to insure dialysis patients who get premium assistance from charity groups.
-
The Orphan Drug Machine
Drugmaker Marathon 鈥楶ausing鈥 Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
By Sarah Jane Tribble and Sydney Lupkin -
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
-
Treating Cancer: Hope Vs. Hype
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
By Liz Szabo -
Georgia Legislative Panel Hears Concerns About Surprise Medical Billing
Insurers and care providers say efforts to fix how consumers are notified also raise concerns.
-
Repeal & Replace Watch
HHS Pick Price Made ‘Brazen’ Stock Trades While His Committee Was Under Scrutiny
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
By Marisa Taylor and Christina Jewett -
The Orphan Drug Machine
KHN Video: Warrior Luke
Luke Whitbeck鈥檚 life was saved by a rare disease drug, but it costs $300,000 a year.
-
Trump鈥檚 Immigration Ban Fuels Fear For Young Doctors Whose Jobs May Be In Limbo
With announcements of placements in residencies expected in March, medical education groups and hospitals say they鈥檙e unsure how to proceed.
-
Women Fear Drug They Used To Halt Puberty Led To Health Problems
Despite questions about Lupron鈥檚 lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
-
Repeal & Replace Watch
Democrats Say Cabinet Choice Tom Price ‘Misled’ The Public. Here’s What We Know.
Concerns over U.S. Rep. Tom Price鈥檚 answers about stock trades led Senate Democrats to boycott a committee vote that would have moved his nomination to the Senate floor.
-
Renewed Cleaning Efforts For Scopes Not Enough To Vanquish Bacteria
A new study, though small, finds extensive damage to commonly used medical scopes that could trap dangerous bacteria. That raises concerns about the potential for more outbreaks.
By Chad Terhune -
Getting Patients Hooked On An Opioid Overdose Antidote, Then Raising The Price
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
-
California Fines Kaiser Permanente $2.5 Million Over Missing Medicaid Data
The HMO blew two deadlines to supply information required by the state to monitor Medi-Cal managed care plans. Kaiser says it is 鈥渢aking steps鈥 to resolve the problem.
By Chad Terhune -
Repeal & Replace Watch
Trump鈥檚 HHS Choice: First A Letter To Medicare. Then A Campaign Contribution.
Rep. Tom Price, up for running HHS under President Trump, helped a company that became a top campaign donor, records show.
By Christina Jewett and Marisa Taylor